Engflag

CELESTAMINE N

Quick links to important sections

CELESTAMINE N

3021188277584955

Method of action: Antiallergic, Antiexudative, Anti-Inflammatory, Antiproliferative, Antipruritic, Corticosteroids For Systemic Use, Corticosteroids, Dermatological Preparations, Decongestant, Glucocorticoid, Immunosuppressive

Treatment option: Allergic Reactions, Allergic Conjunctivitis, Anemia, Ankylosing Spondylitis, Arthritis,Osteoarthritis, Asthma, Atopic Dermatitis, Autoimmune Hemolytic Anemia, Berylliosis, Plaque Psoriasis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of CELESTAMINE N

CELESTAMINE N is a widely known prescription drug used in multiple markets, designed as a synthetic combination product for systemic administration. Its pharmacological identity is defined by the concurrent action of a corticosteroid and a first-generation antihistamine, a pairing used in managing allergic and inflammatory reactions.

Property Description
Active Ingredients Betamethasone, Dexchlorpheniramine maleate
Form Tablet, Syrup
Pharmacological Class Corticosteroid and Antihistamine Combination
General Purpose Managing systemic allergic inflammation
Origin Synthetic

What Type of Medicine is CELESTAMINE N?

CELESTAMINE N is a combination oral medication classified as a blend of anti-inflammatory and anti-allergic agents, primarily supplied as a tablet or syrup. Both of its active compounds, Betamethasone and Dexchlorpheniramine maleate, are of entirely synthetic origin, ensuring purity and consistent potency. As an oral drug, its components are absorbed into the bloodstream to act systemically (throughout the body), which is a key distinguishing feature from localized treatments. Betamethasone is a potent glucocorticoid used to suppress inflammation. This indicates that the medicine has a strong effect in reducing swelling and tissue reaction.

The Dual-Action Composition of CELESTAMINE N

The composition of CELESTAMINE N is strategically engineered to provide two simultaneous therapeutic effects. Its anti-inflammatory power comes from the Betamethasone component, which calms the body's immune response to reduce underlying swelling and hypersensitivity. The anti-allergic effect is delivered by Dexchlorpheniramine maleate, which is a histamine H1 antagonist, blocking the chemical signal responsible for acute allergic symptoms like itching and sneezing. Antihistamines like Dexchlorpheniramine are used to provide relief from symptoms caused by the release of histamine. This confirms the drug's effectiveness in quickly easing common allergy discomfort. The general purpose of this combination is to provide comprehensive relief by targeting both the root inflammatory process and the resulting immediate symptoms of an allergic reaction.

What side effects are possible with CELESTAMINE N?

The safety profile of this medicine is defined by the known risks associated with its two active components: a systemic glucocorticoid (Betamethasone) and a first-generation antihistamine (Dexchlorpheniramine maleate).

Adverse Reaction Scope

Category Officially Documented Safety Characteristics
Key Adverse Reaction Categories Reactions are classified into two main groups: frequent effects related to the antihistamine component and duration-dependent effects related to the corticosteroid component.
Frequency Classification Very Common / Common effects include drowsiness, sedation, somnolence, and dry mouth, which are primarily associated with the antihistamine and may be more pronounced at the start of treatment.
System-Organ Classes Involved Adverse reactions are documented across various systems, including Nervous System Disorders (e.g., sedation), Metabolism and Nutrition Disorders (e.g., fluid retention, weight gain), Musculoskeletal Disorders (e.g., osteoporosis), and Endocrine Disorders (e.g., HPA axis suppression).
Serious Adverse Reactions Clinically significant adverse effects include adrenal cortical suppression (particularly after prolonged use), severe psychiatric disturbances, and potential for peptic ulceration, glaucoma, or cataracts.
Population-Specific Safety Considerations Official safety notes highlight the risk of growth and developmental inhibition in the pediatric population. Caution is also documented for older adults due to increased susceptibility to effects like sedation and fluid retention.
Dose- or Exposure-Related Patterns Severe glucocorticoid effects (e.g., HPA axis suppression, bone density loss) are specifically documented as being associated with prolonged or extended use.
Safety-Related Restrictions or Limitations Contraindications documented in official labeling include systemic fungal infections and situations such as severe hepatic impairment. Caution is noted for use in patients with pre-existing conditions like hypertension or peptic ulcer disease.

Resulting Safety Structure

Regulatory safety summary:

  • The safety profile is dual, comprising frequent acute effects from the antihistamine and serious, duration-dependent effects from the systemic corticosteroid.
  • Official labeling classifies risks across several System-Organ Classes, including the nervous, endocrine, and musculoskeletal systems.
  • Specific warnings are documented for vulnerable populations such as children (growth suppression risk) and older adults.

Connection to the overall safety profile

The official safety information structures the risk understanding by separating common, expected effects linked to treatment initiation from rare or serious risks explicitly linked to the duration of therapy and the specific systems affected by the corticosteroid component. This regulatory framework ensures that the full spectrum of potential adverse outcomes is systematically communicated.

Overdose and Emergency Response

Official Manifestations and Risks

Overdosage of this combination medication is primarily dominated by the effects of the antihistamine component (Dexchlorpheniramine maleate), as documented in regulatory sources. Officially listed manifestations include Central Nervous System (CNS) effects such as extreme sleepiness, confusion, and sometimes paradoxical excitement, particularly in children. Anticholinergic signs, including mydriasis (fixed, dilated pupils), dry mouth, fever, and tachycardia, are also noted.

Official labeling warns of serious or life-threatening outcomes, including the risk of seizures (convulsions), cardiovascular collapse, and the progression of CNS depression to coma. Regulatory guidance notes that death has been reported following massive antihistamine overdosage. CNS stimulation and seizures are particularly associated with overdosage in the pediatric population, while the elderly are more susceptible to severe CNS depression and hypotension.

Emergency Actions and Treatment

Regulators mandate that individuals must seek emergency medical attention immediately for any suspected overdose. This action requires contacting a Poison Control Center or going to the nearest hospital emergency department.

Treatment described in official documents is symptomatic and supportive. No specific antidote is known for this combination. Management procedures include continuous monitoring of vital signs, instituting cardiac monitoring (ECG), managing any seizures that occur, and the administration of activated charcoal to reduce absorption, as specified in regulatory guidance.

Therapeutic Uses of CELESTAMINE N

This medication is generally recommended for the management of difficult cases of allergic and inflammatory disorders. It is generally applied in contexts involving respiratory, dermatologic, and ocular allergic and inflammatory conditions where symptoms require supportive management.

Comprehensive Symptomatic Support

CELESTAMINE N is applied in addressing conditions where the medication is commonly used to address patient discomfort associated with both allergic hypersensitivity and significant inflammation (symptoms related to inflammatory or irritative states). It is used for managing pronounced symptoms like sneezing, persistent itching, and watery eyes, as well as the associated local inflammation such as swelling and redness. This approach is commonly used across conditions presenting with acute episodes, including severe hay fever, allergic rhinitis, urticaria (hives), and other allergic skin conditions.

The medication may contribute to easing the overall symptom load during periods of heightened symptoms.

“It supports the patient during difficult episodes by easing distress and helping them cope more steadily.”

Quick Fact: Relevant for Easing Intense Manifestations

Management of Acute Symptomatic Episodes

This combination is applied in clinical settings marked by heightened symptom intensity that noticeably interferes with daily stability. It is relevant when symptoms cluster into patterns requiring short-term, supportive symptom management, contributing to improved comfort during periods where symptoms create noticeable functional strain.

Regulatory References

  1. Philippine FDA therapeutic guidance

Eligibility and Restrictions for Use

Eligibility Profile: Who Must and Must Not Use This Medicine

The eligibility profile for CELESTAMINE N (Betamethasone/Dexchlorpheniramine Maleate) is formally defined by government regulatory documents, outlining strict contraindications and requirements for restricted use.

Contraindicated Populations (Must Not Use):

Category Regulatory Stipulation
Hypersensitivity Known allergy (hypersensitivity) or idiosyncrasy to any component of the product, including betamethasone or dexchlorpheniramine maleate.
Systemic Infection Patients with active systemic fungal infections.
Age Restriction Newborn and premature infants.
Drug-Drug Interaction Patients currently undergoing MAO inhibitor therapy.
Other Conditions Narrow-angle glaucoma.

Populations Requiring Restricted or Conditional Use:

Use of the medicine requires special consideration and close medical monitoring in patients with specific pre-existing health issues. The prescribing doctor must weigh the risks against the benefits in the following groups:

  • Elderly Patients (over 60 years): Use with caution due to higher risk of side effects, including sedation and anticholinergic effects.
  • Cardiovascular Conditions: Patients with hypertension, recent myocardial infarction, or congestive heart failure.
  • Gastrointestinal Conditions: Patients with active or latent peptic ulcer, ulcerative colitis, diverticulitis, or fresh intestinal anastomoses.
  • Endocrine and Metabolic Issues: Patients with diabetes mellitus, hyperthyroidism, or certain adrenal gland problems.
  • Urinary Obstruction: Patients with prostatic hypertrophy or bladder neck obstruction.
  • Ocular Conditions: Patients with ocular herpes simplex or other forms of glaucoma (caution advised).

Age and Physiological Status:

The medicine's safety and effectiveness have not been established in children under 2 years of age for some formulations. For pregnant or breastfeeding women, use is restricted, and the potential benefits must be carefully weighed against documented potential risks to the fetus or infant.

What should I know about interactions with other medicines?

The official regulatory profile for CELESTAMINE N is structured around the pharmacokinetic and pharmacodynamic interactions of its corticosteroid (Betamethasone) and antihistamine (Dexchlorpheniramine maleate) components. The co-administration of several substance classes results in formally documented constraints and exposure modifications.

Interaction Classification Interacting Substance/Class Official Interaction Pattern
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Prohibited due to intensification of anticholinergic effects; requires a 14-day separation.
Live, Attenuated Vaccines Prohibited when receiving immunosuppressive doses of the corticosteroid.
PK: Reduced Exposure Hepatic Enzyme Inducers (e.g., Rifampin, Phenytoin) Accelerate Betamethasone metabolism, thereby reducing its systemic plasma concentration.
PK: Increased Exposure CYP3A4 Inhibitors (e.g., Ketoconazole) & Estrogens Decrease Betamethasone clearance, resulting in elevated systemic plasma concentrations.
PD: CNS Potentiation CNS Depressants (e.g., Sedatives, Opioids) & Alcohol Create additive effects, potentiating sedation and central nervous system depression.
PD: Risk Augmentation Potassium-Depleting Agents & NSAIDs Increase the risk of hypokalemia (with Diuretics) or gastrointestinal ulceration (with NSAIDs).

Official Regulatory Statements

  • Timing Restriction: The medicine must not be administered within 14 days of discontinuing an MAOI.
  • Population Note: Elderly patients (60 years and older) are formally noted as being more susceptible to the CNS effects, such as dizziness and sedation, associated with the antihistamine component.
  • Drug Effect Modification: Betamethasone may diminish the therapeutic effect of Antidiabetics and Anticholinesterases.

Mechanism of Action

CELESTAMINE N is a combination containing Betamethasone and Dexchlorpheniramine, each with a distinct pharmacodynamic action. The Betamethasone component acts by binding to the intracellular glucocorticoid receptor ( GR), forming a ligand-receptor complex. This complex translocates into the cell nucleus where it functions as a transcription factor, leading to the alteration of gene transcription. This process primarily involves the GR-mediated transrepression of pro-inflammatory transcription factors, such as NF-kappa B. The resulting effect is the inhibited synthesis and subsequent release of pro-inflammatory mediators, including cytokines and prostaglandins. The Dexchlorpheniramine component operates separately as a competitive antagonist at the histamine H1 receptor. By occupying the receptor binding site, it prevents the binding of endogenous histamine and modulates the subsequent H1 receptor-mediated cellular signaling. This concurrent dual-action mechanism influences inflammatory and histamine pathways at a molecular level.

Dosage and Administration Information

Official Administration Guidelines for CELESTAMINE N

The administration of CELESTAMINE N (a combination of Betamethasone and Dexchlorpheniramine) involves specific parameters for dosage and timing.

Dosage Form Route of Administration Strength per Unit
Tablet Oral 0.25 mg Betamethasone / 2 mg Dexchlorpheniramine maleate
Syrup Oral 0.25 mg Betamethasone / 2 mg Dexchlorpheniramine maleate per 5 mL

Dosing and Frequency

Age Group Recommended Initial Dose Frequency and Timing Maximum Daily Dose
Adults & Children (>12 years) 1 to 2 tablets or 1 to 2 teaspoonfuls (5 mL) Four times daily (after meals and at bedtime) 8 tablets or 8 teaspoonfuls
Children (6 to 12 years) 1/2 teaspoonful or 1/2 tablet Three times daily (and preferably an additional dose at bedtime) 4 tablets or 4 teaspoonfuls
Children (2 to 6 years) 1/4 to 1/2 teaspoonful of syrup Three times daily 2 teaspoonfuls

Procedural and Adjustment Rules

  • Dose Individualization: The prescribed dose must be customized to the individual patient’s requirements and adjusted based on the response to the medicine and the severity of the condition.
  • Lowest Effective Dose: The treatment must be managed using the lowest possible dose required to control the condition. Dosage adjustments should be made as the condition improves or worsens.
  • Administration Specifics: The syrup formulation must be measured using an accurate measuring device; household spoons should not be used. The tablets should be taken without breaking, cracking, or chewing.
  • Discontinuation: This medicine should not be stopped suddenly. Long-term or high-dose therapy requires a gradual dosage reduction (tapering) when discontinuing to prevent potential adverse symptoms.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Research regarding the combination drug CELESTAMINE N (betamethasone/dexchlorpheniramine) primarily focuses on its components' established use in allergic and inflammatory conditions. Clinical evidence centers on assessing safety, comparing the combination to other treatments, and evaluating effects on specific symptoms.

Findings from Clinical Studies

Clinical trials involving the drug combination or its components have focused on outcomes related to allergic diseases, such as seasonal and perennial allergic rhinitis.

  • Efficacy Studies: Controlled trials have evaluated the drug's effect on total symptom scores (TSS), including symptoms like sneezing, nasal congestion, nasal itching, and rhinorrhea. Studies compared the combination to single-agent therapy, with results providing data on changes in symptom severity across patient groups.
  • Long-Term Monitoring: Safety assessments of long-term use, particularly relating to the corticosteroid component, have been conducted to monitor the incidence of adverse events (AEs), including systemic effects associated with prolonged glucocorticoid use.

Safety and Comparative Assessments

Comparative research examines the drug against monotherapy and other treatments, focusing on both efficacy outcomes and reported adverse events.

  • Combination vs. Monotherapy: Early studies evaluated the combination therapy compared to monotherapy in patients who had not responded to initial treatment. Safety assessments of the combination have been conducted, with results comparing the reported adverse events to the drug alone in the study participants.
  • Specific Patient Groups: Studies have included participants with specific pre-existing conditions for assessment, providing data on adverse events reported in these particular groups. For instance, data exists on the effects of discontinuing long-term use, highlighting the need for supervised tapering due to potential steroid withdrawal effects.

Frequently Asked Questions (FAQ)

Common questions about CELESTAMINE N (FAQ)

Q: What should I use to measure the syrup dose?

Official administration guidelines state that the syrup formulation should be measured using an accurate, calibrated measuring device. It is specifically noted that household spoons should not be used, as they may lead to inaccurate dosing.

Q: How should I dispose of expired CELESTAMINE N?

The product labeling indicates that disposal should adhere to local regulations. General guidance recommends discarding the product via an approved waste disposal plant. Consult your local waste procedures for specific instructions.

Q: What are the most common side effects?

Regulatory documents classify very common or common effects as drowsiness, sedation, somnolence, and dry mouth. These effects are primarily associated with the antihistamine component and may be more pronounced when treatment is first initiated.

Q: Is CELESTAMINE N safe to take during pregnancy?

Official product information notes that use of this medicine during pregnancy is limited. Potential benefits must be carefully weighed against documented potential risks to the fetus or infant by the prescribing physician.

Q: What conditions is CELESTAMINE N specifically approved to treat?

Regulatory information indicates the drug is approved for the management of difficult cases of various allergies, including respiratory, dermatologic, and ocular types. It is specifically intended for conditions where adjunctive systemic corticosteroid therapy is necessary.

Q: Can I drink grapefruit juice while taking this medicine?

One of the active ingredients, Betamethasone, is metabolized by the CYP3A4 enzyme. Since grapefruit juice may inhibit this enzyme, there is a potential for interaction that could lead to increased systemic concentrations of the medicine.

How should CELESTAMINE N be stored and disposed of?

Official Storage and Disposal Requirements

CELESTAMINE N must be stored under specific conditions to maintain its stability, as mandated by regulatory documents. The required storage environment is Controlled Room Temperature, which is typically 20^circ to 25 C (68^circ to 77 F), with permitted brief excursions up to 30 C (86 F). The medication must be protected from light and excessive moisture and stored in a cool, dry place. It is required to dispense the product in a tight, light-resistant container and ensure the integrity of the original packaging is maintained.

For safety, the medicine must be strictly kept out of the reach of children and should be dispensed with a child-resistant closure. Disposal of unused or expired CELESTAMINE N must adhere to local regulations. Users must consult their local waste procedures, and general guidance recommends discarding the product via an approved waste disposal plant.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGermany

Equivalent of CELESTAMINE N found in:

A-Z Index: